{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+20mg", "query": { "intervention": "Dexamethasone 20mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 67, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+20mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T08:05:37.505Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03590652", "title": "Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-10-17", "completion_date": "2025-07-02", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03590652" }, { "nct_id": "NCT03104270", "title": "Combination Study for High Risk Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-03-13", "completion_date": "2020-01-23", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 6, "location_summary": "Encinitas, California • Fountain Valley, California • Monterey, California + 3 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104270" }, { "nct_id": "NCT04181827", "title": "A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 419, "start_date": "2020-06-12", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04181827" }, { "nct_id": "NCT00538824", "title": "Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2007-12", "completion_date": "2010-09-22", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538824" }, { "nct_id": "NCT00083915", "title": "DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2001-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083915" }, { "nct_id": "NCT02219581", "title": "Steroids in Total Knee Arthroplasty", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Pain", "Inflammation", "Osteoarthritis" ], "interventions": [ { "name": "Dexamethasone 10 mg", "type": "DRUG" }, { "name": "Dexamethasone 20 mg", "type": "DRUG" }, { "name": "Standard multimodal pain management regimen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas L Bradbury", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1, "start_date": "2014-10-16", "completion_date": "2015-12-01", "has_results": true, "last_update_posted_date": "2022-10-04", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 1, "location_summary": "Tucker, Georgia", "locations": [ { "city": "Tucker", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219581" }, { "nct_id": "NCT03110562", "title": "Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2017-05-24", "completion_date": "2022-05-12", "has_results": true, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 20, "location_summary": "Plantation, Florida • Atlanta, Georgia • Honolulu, Hawaii + 16 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Ames", "state": "Iowa" }, { "city": "Topeka", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110562" }, { "nct_id": "NCT05205252", "title": "A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Hematologic Malignancy", "Refractory Hematologic Malignancy" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Daratumumab (Intravenously)", "type": "DRUG" }, { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Daratumumab (Subcutaneously)", "type": "DRUG" }, { "name": "Hyaluronidase-Fihj", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone 20mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-12-22", "completion_date": "2023-07-05", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 3, "location_summary": "Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey", "locations": [ { "city": "Santa Fe", "state": "California" }, { "city": "Bolivar", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05205252" }, { "nct_id": "NCT04984330", "title": "Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Amyloid", "Amyloidosis", "AL Amyloidosis" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-12", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2022-11-17", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04984330" }, { "nct_id": "NCT00064337", "title": "S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Myeloma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 104, "start_date": "2004-01", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-09-20T08:05:37.505Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Salina", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064337" } ] }